[go: up one dir, main page]

MA26787A1 - Inhibiteurs renin - Google Patents

Inhibiteurs renin

Info

Publication number
MA26787A1
MA26787A1 MA26386A MA26386A MA26787A1 MA 26787 A1 MA26787 A1 MA 26787A1 MA 26386 A MA26386 A MA 26386A MA 26386 A MA26386 A MA 26386A MA 26787 A1 MA26787 A1 MA 26787A1
Authority
MA
Morocco
Prior art keywords
renin inhibitors
renin
inhibitors
Prior art date
Application number
MA26386A
Other languages
English (en)
Inventor
Hans-Peter Maerki
Wolfgang Wostl
Volker Breu
Eric Vieira
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26787A1 publication Critical patent/MA26787A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
MA26386A 1999-04-27 2001-10-26 Inhibiteurs renin MA26787A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99108199 1999-04-27

Publications (1)

Publication Number Publication Date
MA26787A1 true MA26787A1 (fr) 2004-12-20

Family

ID=8238050

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26386A MA26787A1 (fr) 1999-04-27 2001-10-26 Inhibiteurs renin

Country Status (35)

Country Link
US (2) US6376672B1 (fr)
EP (1) EP1175400B1 (fr)
JP (1) JP3808706B2 (fr)
KR (1) KR100443684B1 (fr)
CN (1) CN1147471C (fr)
AR (2) AR018719A1 (fr)
AT (1) ATE512949T1 (fr)
AU (1) AU763718B2 (fr)
BR (1) BR0010080B1 (fr)
CA (1) CA2370888C (fr)
CO (1) CO5170513A1 (fr)
CZ (1) CZ302012B6 (fr)
DK (1) DK1175400T3 (fr)
EG (1) EG23979A (fr)
ES (1) ES2366668T3 (fr)
GC (1) GC0000251A (fr)
HK (1) HK1045999B (fr)
HR (1) HRP20010762A2 (fr)
HU (1) HU227764B1 (fr)
IL (2) IL146002A0 (fr)
JO (1) JO2256B1 (fr)
MA (1) MA26787A1 (fr)
MX (1) MXPA01010934A (fr)
MY (1) MY127894A (fr)
NO (1) NO320803B1 (fr)
NZ (1) NZ514981A (fr)
PE (1) PE20010069A1 (fr)
PL (1) PL199895B1 (fr)
PT (1) PT1175400E (fr)
RS (1) RS51156B (fr)
RU (1) RU2213731C2 (fr)
TR (1) TR200103095T2 (fr)
TW (1) TWI224593B (fr)
WO (1) WO2000064873A1 (fr)
ZA (1) ZA200108735B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376672B1 (en) * 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
US6835686B2 (en) * 2001-07-05 2004-12-28 Millennium Specialty Chemicals Catalyst system and process for rearrangement of epoxides to allylic alcohols
BR0312000A (pt) * 2002-06-27 2005-03-22 Actelion Pharmaceuticals Ltd Compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, uso dos compostos
US20040214832A1 (en) * 2003-04-10 2004-10-28 Cuiman Cai Piperazine derivative renin inhibitors
KR20060007041A (ko) * 2003-04-29 2006-01-23 액테리온 파마슈티칼 리미티드 신규의 3,4-이치환된 1,2,3,6-테트라하이드로피리딘 유도체
TW200900399A (en) 2003-10-01 2009-01-01 Speedel Experimenta Ag Organic compounds
AR045950A1 (es) * 2003-10-09 2005-11-16 Speedel Experimenta Ag Compuestos derivados de piperazina, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos.
US20050209141A1 (en) * 2003-10-17 2005-09-22 Silver Randi B Mast cell-derived renin
DE602004022704D1 (de) * 2003-11-26 2009-10-01 Novartis Ag 4-phenylpiperidinderivate als renininhibitoren
AR053406A1 (es) * 2004-07-09 2007-05-09 Speedel Experimenta Ag Derivados de piperidina como inhibidores de renina. composiciones farmaceuticas
MX2007004020A (es) 2004-10-08 2007-05-24 Novartis Ag Uso de inhibidores de renina para la prevencion o tratamiento de disfuncion diastolica o falla cardiaca diastolica.
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
GB0500784D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
TW200722424A (en) * 2005-03-31 2007-06-16 Speedel Experimenta Ag Substituted piperidines
EP1897879A3 (fr) * 2005-03-31 2008-06-11 Speedel Experimenta AG Pipéridines 2,4,5-substituées comme inhibiteurs de la rénine
EP1707202A1 (fr) * 2005-03-31 2006-10-04 Speedel Experimenta AG Composes organiques
AR055756A1 (es) * 2005-03-31 2007-09-05 Speedel Experimenta Ag Piperidinas sustituidas; procesos de preparacion y su uso como medicamentos
EP1863763A1 (fr) * 2005-03-31 2007-12-12 Speedel Experimenta AG Piperidine a substitution 3,4,5 utiles en tant qu'inhibiteurs de la renine
CN101151262B (zh) * 2005-03-31 2011-07-06 斯皮德尔实验股份公司 取代的哌啶
EP1893578A2 (fr) 2005-05-27 2008-03-05 Actelion Pharmaceuticals Ltd. Nouveaux derives d'amide d'acide piperidine carboxylique
GB0514203D0 (en) * 2005-07-11 2005-08-17 Novartis Ag Organic compounds
RU2008119687A (ru) * 2005-10-21 2009-11-27 Новартис АГ (CH) Комбинации органических соединений
CN101356156B (zh) * 2005-11-14 2012-12-05 生命医药公司 天冬氨酸蛋白酶抑制剂
CA2633624C (fr) * 2005-12-30 2013-11-19 Novartis Ag Derives de piperidine 3,5-substitues en tant qu'inhibiteurs de renine
EP1816122A3 (fr) * 2006-01-19 2007-09-19 Speedel Experimenta AG Pipéridines substituées 3,4,5 en tant que composants thérapeutiques
TW200804359A (en) * 2006-01-19 2008-01-16 Speedel Experimenta Ag Substituted 4-phenylpiperidines
TW200821303A (en) * 2006-08-08 2008-05-16 Speedel Experimenta Ag Organic compounds
WO2008021552A2 (fr) * 2006-08-18 2008-02-21 Duke University Ligands biaisés et leurs procédés d'identification
EP1908761A1 (fr) * 2006-10-04 2008-04-09 Speedel Experimenta AG Composés organiques
EP1911758A1 (fr) * 2006-10-04 2008-04-16 Speedel Experimenta AG Derivés de phenyl-piperidine comme inhibiteurs de renin
ES2541107T3 (es) 2007-06-25 2015-07-16 Novartis Ag Derivados de N5-(2-etoxietil)-N3-(2-piridinil)-3,5-piperidindicarboxamida para su uso como inhibidores de renina
AR069145A1 (es) * 2007-11-02 2009-12-30 Speedel Experimenta Ag Piperidinas 4,4- disusutituidas, uso del compuesto en la produccion de un medicamento, un producto farmaceutico en base al compuesto y un metodo de prevencion de enfermedades
US10517839B2 (en) 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
WO2011045244A1 (fr) 2009-10-14 2011-04-21 Rainer Oberbauer Test de risque de lésion rénale aigüe
WO2013045505A1 (fr) 2011-09-28 2013-04-04 Novartis Ag Biomarqueurs pour traitement combiné par des agents sraa
EP2810644A1 (fr) 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Formulation orale pour le traitement de maladies cardiovasculaires
WO2018002673A1 (fr) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Nouvelles formulations d'antagonistes du récepteur de l'angiotensine ii

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4868181A (en) * 1986-08-04 1989-09-19 E. I. Du Pont De Nemours And Company 1,4-dihydropyridine derivatives with calcium agonist and alpha1 -antagonist activity
DK231088D0 (da) 1988-04-28 1988-04-28 Ferrosan As Piperidinforbindelser, deres fremstilling og anvendelse
DE3640475A1 (de) 1986-11-27 1988-06-09 Hoechst Sa Lab Arzneimittel auf basis von derivaten des 3,4-diphenylpiperidins, die verwendung der derivate als arzneimittel sowie neue 3,4-diphenylpiperidinderivate und verfahren zu ihrer herstellung
EP0594618B1 (fr) 1991-06-24 1996-04-24 B.V. Optische Industrie "De Oude Delft" Dispositif mesurant la respiration d'une personne
AU6735396A (en) 1995-07-24 1997-02-18 Railfix N.V. Electrical permanent-magnet system for manoeuvring a magnetic, particularly a ferromagnetic, load
CZ292327B6 (cs) 1995-09-07 2003-09-17 F. Hoffmann-La Roche Ag Derivát 4-(oxyalkoxyfenyl)-3-oxypiperidinu, způsob jeho přípravy, meziprodukt pro jeho přípravu a farmaceutický prostředek, který ho obsahuje
WO1999012532A2 (fr) * 1997-09-08 1999-03-18 F.Hoffmann-La Roche Ag Derives de piperidine contre la malaria
US6376672B1 (en) * 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors

Also Published As

Publication number Publication date
AR070473A2 (es) 2010-04-07
US20020087002A1 (en) 2002-07-04
AR018719A1 (es) 2001-11-28
NZ514981A (en) 2004-02-27
IL146002A0 (en) 2002-07-25
CN1147471C (zh) 2004-04-28
HK1045999B (zh) 2004-10-21
PL199895B1 (pl) 2008-11-28
BR0010080B1 (pt) 2012-03-20
PE20010069A1 (es) 2001-03-03
EP1175400B1 (fr) 2011-06-15
CA2370888C (fr) 2005-08-23
KR20010109529A (ko) 2001-12-10
ZA200108735B (en) 2003-01-23
ATE512949T1 (de) 2011-07-15
CO5170513A1 (es) 2002-06-27
PT1175400E (pt) 2011-08-11
JP3808706B2 (ja) 2006-08-16
HK1045999A1 (en) 2002-12-20
RS51156B (sr) 2010-10-31
MXPA01010934A (es) 2002-05-06
JO2256B1 (en) 2004-10-07
JP2002543063A (ja) 2002-12-17
MY127894A (en) 2006-12-29
NO20015206L (no) 2001-10-25
GC0000251A (en) 2006-11-01
BR0010080A (pt) 2002-01-15
YU77101A (sh) 2004-09-03
HRP20010762A2 (en) 2005-02-28
EG23979A (en) 2008-02-27
CZ302012B6 (cs) 2010-09-08
CN1349503A (zh) 2002-05-15
NO20015206D0 (no) 2001-10-25
HUP0203669A2 (hu) 2003-02-28
US6376672B1 (en) 2002-04-23
US6673931B2 (en) 2004-01-06
ES2366668T3 (es) 2011-10-24
TWI224593B (en) 2004-12-01
CZ20013854A3 (cs) 2002-04-17
DK1175400T3 (da) 2011-07-18
PL353442A1 (en) 2003-11-17
AU763718B2 (en) 2003-07-31
KR100443684B1 (ko) 2004-08-09
HUP0203669A3 (en) 2003-12-29
IL146002A (en) 2007-03-08
EP1175400A1 (fr) 2002-01-30
HU227764B1 (en) 2012-02-28
AU4296800A (en) 2000-11-10
RU2213731C2 (ru) 2003-10-10
CA2370888A1 (fr) 2000-11-02
NO320803B1 (no) 2006-01-30
TR200103095T2 (tr) 2002-04-22
WO2000064873A1 (fr) 2000-11-02

Similar Documents

Publication Publication Date Title
ATE512949T1 (de) Reninhemmer
ATE363478T1 (de) Renin inhibitoren
PT1181017E (pt) Inibidores de metaloproteases
PT1224195E (pt) C-aril-glicosidos inibidores de tgls2
ATE285821T1 (de) Fab i inhibitoren
EE200100492A (et) Ensüümi IMPDH inhibiitorid
PT1194404E (pt) Inibidores de aspartil-protease
ATE524441T1 (de) Vla-4-inhibitoren
EE200200069A (et) Metalloproteinaaside inhibiitoriteks olevad pürimidiin-3,4,6-trioonid
DE60008527D1 (de) Zellproliferation inhibitoren
DK1272488T3 (da) Tri-aryl-substitueret ethan-PDE4-inhibitorer
NO20014243L (no) Dihetero-substituerte metalloproteaseinhibitorer
IS6413A (is) Setnir 8-arýkínólín fosfódíesterasa-4 latar
NO20021658L (no) Asfaltenhemmere
NO20014875D0 (no) Promedikamenter for trombin inhibitorer
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
DE60024101D1 (de) Enzyminhibitoren
DE60009260D1 (de) Thiopyranderivate as mmp-inhibitoren
NO20022924L (no) Farnesyltransferase-inhibitorer
AR028075A1 (es) Inhibidores de la peptido-desformilasa
EP1234581A4 (fr) Inhibiteurs de contraction de blessure
IDP000027420A (id) Inhibitor-inhibitor kinase pirolotriazin